LL-37 vs Pentosan Polysulfate
A side-by-side research comparison of LL-37 and Pentosan Polysulfate across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | LL-37 | Pentosan Polysulfate |
|---|---|---|
| Full name | Cathelicidin Antimicrobial Peptide LL-37 | Pentosan Polysulfate Sodium |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | FDA Approved |
| Mechanism | Disrupts microbial membranes, neutralizes endotoxins, recruits immune cells via chemotaxis, and promotes angiogenesis and re-epithelialization. | Acts as a glycosaminoglycan analog that coats bladder mucosa, inhibits complement activation, and stimulates proteoglycan synthesis in cartilage. |
| Molecular weight | 4493.33 Da | 4000-6000 Da (average) |
| Half-life | ~4-6 hours | ~24 hours |
| Bioavailability | Variable by route; topical and injectable | ~3-6% oral; higher via injection |
| Typical dose | 50-100 mcg | 100 mg |
| Frequency | Daily | 3x daily (oral) |
| Route | Topical or subcutaneous injection | Oral or subcutaneous injection |
LL-37 reported benefits
- Broad-spectrum antimicrobial
- Wound healing acceleration
- Biofilm disruption
- Immune system enhancement
Pentosan Polysulfate reported benefits
- Bladder wall protection
- Cartilage repair support
- Anti-inflammatory action
- Joint pain reduction
Related comparisons
Research and educational reference only. Not medical advice.